Dermatology Lead ImageneBio's lead antibody IMG-007 is a receptor-targeting, non-depleting anti-OX40 with ADCC silencing and extended half-life, currently in Phase 2b for moderate-to-severe atopic dermatitis after Phase 1b/2a for dermatitis and alopecia areata. This profile makes IMG-007 a strong candidate for licensing or co-development by dermatology-focused partners seeking a differentiated, safety-conscious immunotherapy.

Licensing Opportunity The ongoing Phase 2b in atopic dermatitis presents a near-term value proposition for strategic partners to accelerate late-stage development and potential commercialization without a full internal build-out. Partners could leverage ImageneBio's assets for regional rights, while ImageneBio retains development milestones and royalties.

Funding Signals A $30 million private placement in April 2026 and active investor engagement at conferences indicate readiness for partnerships and co-funding deals to advance IMG-007. BD teams could use this signal to propose milestone-driven collaborations and potential upfront economics.

Global Expansion ImageneBio's US-based operations and dermatology focus create opportunities for out-licensing in Europe and Asia-Pacific, potentially through regional partnerships or strategic alliances with established dermatology portfolios.

Partnership Needs With a small team and Phase 2b activities, ImageneBio may benefit from CRO/CDMO and manufacturing partnerships to support clinical trials, as well as regulatory strategy and biomarker collaboration to de-risk late-stage advancement.